ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development Post author: Post published: November 13, 2023 Post category:uncategorized ATCC today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. You Might Also Like Fifteen-year study shows major gains in diabetes technology use and patient outcomes August 11, 2025 CEPI and University of Oxford launch new project to initiate vaccine development against Junín virus November 6, 2023 Chronic alcohol use profoundly alters gene expression in the brain’s reward system February 9, 2026
CEPI and University of Oxford launch new project to initiate vaccine development against Junín virus November 6, 2023